Servier at a glance
Servier is an independent research-based pharmaceutical company headquartered in France. With a strong international presence in 148 countries and 92% of its medicines being prescribed outside of France, Servier employs more than 21,200 people worldwide. In 2015, the company recorded a turnover of 3.9 billion euros of which 24% was reinvested in research and development.
Our journey in oncology started in the 90s with Muphoran a chemotherapy drug used to treat melanoma, a skin cancer. In 2014, we launched Pixuvri in multiple relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. On April 27th, 2016, we have received a marketing approval for LONSURF® (trifluridine/tipiracil) in the field of advanced metastatic colorectal cancer.
Currently, there are eight new molecular entities in clinical development for oncology respectively in breast, lung and other solids tumors as well as various leukemias and lymphomas.
This portfolio of innovative cancer treatments is being developed with various partners worldwide, and covers different hallmarks of cancer including cytotoxics, proapoptotic, targeted, immune and cellular therapies.
Our leadership team
Our leadership includes our President, who manages and represents the Foundation in its relations with third parties. And our Executive Committee that is comprised of the President of the Foundation and of our Senior Executive Vice-Presidents. Our President submits the essential aspects of the group’s general policy and planned strategic operations to our SEVPs for approval. They ensure we deliver our promise by putting the patient and ethics at the heart of everything we do.